AAM
AMED

Alpine Associates Management’s Amedisys AMED Stock Holding History

Alpine Associates Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,096,920
Closed -$108M – 69
2025
Q2 		$108M Buy
1,096,920
+104,800
+11% +$9.92M 5.76% 6
2025
Q1 		$91.9M Buy
992,120
+104,000
+12% +$9.59M 4.81% 7
2024
Q4 		$80.6M Buy
888,120
+27,403
+3% +$2.52M 4.89% 7
2024
Q3 		$83.1M Sell
860,717
-420,180
-33% -$41M 3.81% 10
2024
Q2 		$118M Buy
1,280,897
+11,000
+0.9% +$1.02M 5.63% 4
2024
Q1 		$117M Sell
1,269,897
-1,200
-0.1% -$112K 4.56% 7
2023
Q4 		$121M Buy
1,271,097
+237,600
+23% +$22.2M 6.2% 4
2023
Q3 		$96.5M Buy
1,033,497
+328,300
+47% +$30.3M 5.06% 9
2023
Q2 		$64.5M Buy
+705,197
New +$57.9M 2.9% 16

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $136M AUM 59.34% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Alpine Associates Management's AMED Position: Q3 2025 in Review

Alpine Associates Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 1,096,920 shares — an estimated $108M sold.

Alpine Associates Management first reported a position in AMED in Q2 2023 and held it in 9 quarters. The position peaked at $121M in Q4 2023. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Alpine Associates Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Alpine Associates Management sold 1,096,920 Amedisys shares in Q3 2025, an estimated $108M.
  • Alpine Associates Management first reported a position in Amedisys in Q2 2023 and held it in 9 quarters.
  • Alpine Associates Management's Amedisys position peaked at $121M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Alpine Associates Management's 13F filing for Q3 2025, filed 6 Nov 2025.